Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
762 studies found for:    Open Studies | "Carcinoma, Bronchogenic"
Show Display Options
Rank Status Study
1 Recruiting SAS in Patients With Bronchial Carcinoma
Conditions: Sleep Apnea Syndrome;   Bronchial Carcinoma
Intervention: Device: sleep apnea screening with ApneaLinkTM
2 Unknown  Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy
Condition: Squamous Cell Carcinoma of Bronchus
Intervention: Drug: Gefitinib
3 Unknown  Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)
Condition: Recurrent Small Cell Lung Cancer
Intervention: Drug: Bendamustin/Ribomustin
4 Recruiting Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)
Conditions: Lung Cancer;   Non-small Cell Lung Cancer (NSCLC)
Interventions: Drug: Dasatinib - 1A;   Drug: Afatinib - 1A;   Drug: Dasatinib - 1B;   Drug: Afatinib - 1B
5 Recruiting Comparison of Different Types of Surgery in Treating Patients With Early-stage Non-small Cell Lung Cancer
Conditions: Stage IA Non-small Cell Lung Cancer;   Adenocarcinoma of the Lung;   Squamous Cell Lung Cancer
6 Recruiting Correlation Research of Thioredoxin Reductase in Lung Cancer
Conditions: Non-small Cell Lung Cancer;   Benign Neoplasm of Lung
7 Recruiting A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations
Conditions: Non-Small-Cell Lung Cancer (NSCLC);   Epidermal Growth Factor Receptor Mutations
Interventions: Drug: ASP8273;   Drug: midazolam
8 Not yet recruiting Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Chemotherapy;   Drug: BI 695502;   Drug: bevacizumab
9 Recruiting Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: Afatinib
10 Recruiting Chemotherapy for Lung Cancer in HIV-positive Patients
Conditions: Non-small Cell Lung Cancer;   Hiv-positive
Intervention: Drug: Chemotherapy
11 Unknown  The Study of Gemcitabine in the Maintenance Treatment of Advanced Non-small Cell Lung Cancer
Condition: THE Efficacy and Safety of Gemcitabine in the Maintenance Treatment of Advanced Non-small Cell Lung Cancer
Intervention: Drug: gemcitabine
12 Recruiting Phase II Trial of Double Dose of Icotinib in Treating Brain Metastases From Non-small Cell Lung Cancer
Conditions: Brain Metastases;   Non-small Cell Lung Cancer
Intervention: Drug: Icotinib
13 Recruiting A Study of PC Sequential Pemetrexed Single Drug Maintenance Treatment for NSCLC and Related Predictive Biomarkers
Condition: Non-small Cell Lung Cancer
Intervention: Drug: pemetrexed /carboplatin
14 Recruiting Observing Patients With Palliative Asymptomatic Centrally Located Advanced Non-small Cell Lung Carcinoma (NSCLC)
Condition: Non-small Cell Lung Carcinoma
Intervention: Other: None: Questionnaire Study
15 Recruiting Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
Condition: Non-Small Cell Lung Cancer
Intervention: Drug: Cabozantinib
16 Not yet recruiting Immune Boost In Non-Small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer
Intervention: Radiation: Preoperative radiation
17 Recruiting A Study Examining Long Response in Lung Cancer Patients Treated With Tarceva (Erlotinib)
Condition: Non-Small Cell Lung Cancer
18 Available Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
Condition: Non-small Cell Lung Cancer (NSCLC)
Intervention: Drug: LDK378
19 Recruiting VEGFRs Predict Bevacizumab Benefit in Advanced Non Small Cell Lung Cancer
Conditions: Non Small Cell Lung Cancer;   Brain Metastasis
Intervention: Other: bevacizumab, standard chemotherapy and radiation
20 Not yet recruiting Phase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21
Condition: Non-small Cell Lung Cancer
Interventions: Other: Erlotinib w Concurrent Radiotherapy;   Other: etoposide/cis-platin (EP) w Concurrent Radiotherapy

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years